Sakurai, Masatoshi http://orcid.org/0000-0002-6687-4136
Ishitsuka, Kantaro
Ito, Ryoji http://orcid.org/0000-0003-2903-2332
Wilkinson, Adam C. http://orcid.org/0000-0001-7406-0151
Kimura, Takaharu
Mizutani, Eiji http://orcid.org/0000-0003-0301-6780
Nishikii, Hidekazu http://orcid.org/0000-0002-6277-4082
Sudo, Kazuhiro
Becker, Hans Jiro http://orcid.org/0000-0003-3058-9859
Takemoto, Hiroshi http://orcid.org/0000-0001-9893-0609
Sano, Tsubasa http://orcid.org/0000-0002-7979-4143
Kataoka, Keisuke
Takahashi, Satoshi http://orcid.org/0000-0002-1076-2338
Nakamura, Yukio http://orcid.org/0000-0001-6834-4123
Kent, David G. http://orcid.org/0000-0001-7871-8811
Iwama, Atsushi http://orcid.org/0000-0001-9410-8992
Chiba, Shigeru
Okamoto, Shinichiro
Nakauchi, Hiromitsu http://orcid.org/0000-0002-9841-6973
Yamazaki, Satoshi http://orcid.org/0000-0003-4249-3854
Article History
Received: 10 March 2022
Accepted: 18 January 2023
First Online: 22 February 2023
Competing interests
: M.S. and S.Y. are co-founders and shareholders in Celaid Therapeutics. H. Nakauchi is a co-founder and shareholder in Megakaryon, Century Therapeutics and Celaid Therapeutics. The remaining authors declare no competing interests.